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AbsTrACT
Objective gastric infection with Helicobacter pylori is a 
strong risk factor for non-cardia gastric adenocarcinoma. 
the aim of this study was to assess whether the risk 
of gastric adenocarcinoma and non-cardia gastric 
adenocarcinoma decreases after eradication treatment 
for H. pylori in a Western population.
Design this was a nationwide, population-based 
cohort study in Sweden in 2005–2012. Data from the 
Swedish Prescribed Drug registry provided information 
on H. pylori eradication treatment, whereas information 
concerning newly developed gastric adenocarcinoma 
was retrieved from the Swedish cancer registry. the 
risk of gastric adenocarcinoma and non-cardia gastric 
adenocarcinoma in individuals who had received H. 
pylori eradication treatment was compared with the 
background population of the corresponding age, sex 
and calendar year distribution, yielding standardised 
incidence ratios (Sirs) with 95% cis.
results During the follow-up of 95 176 individuals 
who had received eradication treatment (351 018 
person-years at risk), 75 (0.1%) developed gastric 
adenocarcinoma and 69 (0.1%) developed non-
cardia gastric adenocarcinoma. the risk of gastric 
adenocarcinoma decreased over time after eradication 
treatment to levels below that of the corresponding 
background population. the Sirs were 8.65 (95% ci 
6.37 to 11.46) for 1–3 years, 2.02 (95% ci 1.25 to 
3.09) for 3–5 years and 0.31 (95% ci 0.11 to 0.67) for 
5–7.5 years after eradication treatment. When restricted 
to non-cardia adenocarcinoma, the corresponding Sirs 
were 10.74 (95% ci 7.77 to 14.46), 2.67 (95% ci 1.63 
to 4.13) and 0.43 (95% ci 0.16 to 0.93).
Conclusion eradication treatment for H. pylori seems to 
counteract the development of gastric adenocarcinoma 
and non-cardia gastric adenocarcinoma in this Western 
population.
InTrODuCTIOn
Globally, gastric cancer (95% adenocarcinoma) is the 
fifth most common cancer (incidence rate 16.1 per 
100 000 individuals) and the second most common 
cause of cancer death (death rate 13.8 per 100 000 
individuals).1 The highest incidence is found in 
Asian populations, and the lowest in Western popu-
lations.1 In Sweden (a Western population), the 
incidence rates are 10.4 and 6.4 per 100 000 indi-
viduals in men and women, respectively.2 Infection 
with the bacterium Helicobacter pylori is associated 
with an increased risk of non-cardia gastric adeno-
carcinoma, whereas the risk of cardia gastric adeno-
carcinoma is not increased.3 Worldwide, around 
half of the population is infected, with higher rates 
in Asia and Central and South America and lower 
rates in Western populations.4 The H. pylori preva-
lence in Sweden is around 15%, which is relatively 
low.5 Of those infected, it is estimated that the life-
time risk of developing gastric adenocarcinoma is 
around 3%.6 
H. pylori eradication, used for treatment of 
functional dyspepsia and the prevention of recur-
rent peptic ulcer after an earlier ulcer episode, has 
been found to prevent gastric cancer in meta-anal-
yses, showing a 50% risk reduction.7 8 However, 
these meta-analyses almost exclusively included 
studies from Asian populations. Thus, there is 
a need to estimate the role of H. pylori eradica-
tion treatment in the prevention of gastric cancer 
in large-scale studies from Western populations 
with specific analyses of the risk of non-cardia 
adenocarcinoma. Therefore, this study aimed 
to assess the risk of gastric adenocarcinoma 
and of non-cardia gastric adenocarcinoma after 
significance of this study
What is already known on this subject?
 ► The strongest risk factor for non-cardia gastric 
adenocarcinoma is gastric infection with 
Helicobacter pylori.
 ► Only a small percentage (3%) of those infected 
with H. pylori develop non-cardia gastric 
adenocarcinoma.
 ► Eradication of H. pylori is associated with 
a reduced risk of gastric cancer in Asian 
populations.
What are the new findings?
 ► This study assessed the role of H. pylori 
eradication treatment in the prevention of 
gastric adenocarcinoma in a large population-
based study, using data from high-quality 
nationwide Swedish registers.
 ► The risk of gastric adenocarcinoma (non-cardia 
adenocarcinoma in particular) sharply 
decreased from 5 years onwards after 
eradication treatment for H. pylori.
How might it impact on clinical practice in the 
foreseeable future?
 ► The findings of this study may contribute to a 
better understanding of the risks and benefits 
of eradication therapy in regions with a low 
prevalence of gastric cancer.
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eradication treatment for H. pylori in a nationwide Swedish 
cohort study.
MATerIAls AnD MeTHODs
study design
This was a population-based, nationwide cohort study in 
Sweden, based on an a priori established study protocol. The 
exposure was eradication treatment for H. pylori, and the 
outcomes were gastric adenocarcinoma and non-cardia gastric 
adenocarcinoma. Eligible for inclusion were all individuals 
residing in Sweden aged 18 years and older who received 
eradication treatment for H. pylori during 1 July 2005 to 
31 December 2012. The cohort has been described in more 
detail in a descriptive study on the use of eradication treat-
ment for H. pylori in Sweden.9
exposure
Individuals were considered exposed if they received at least 
one prescription and dispensing of a recommended eradica-
tion regimen for H. pylori. Eradication treatment for H. pylori 
in Sweden usually consists of a combination of a proton pump 
inhibitor together with the antibiotics amoxicillin and clari-
thromycin for 7 days.9 The following prescriptions are avail-
able in Sweden for recommended eradication treatment of 
H. pylori (specified by the Anatomical Therapeutic Chemical 
code):
A specific H. pylori eradication package that includes the 
proton pump inhibitor esomeprazole and the antibiotics 
amoxicillin and clarithromycin (A02BD06);
Separate prescriptions of a proton pump inhibitor (A02BC) 
together with two of the following antibiotics: amoxicillin 
(J01CA04) and clarithromycin (J01FA09) or metronidazole 
(J01XD01).
For the separate prescriptions, no other antibiotics were 
to be prescribed at the same time to be considered a recom-
mended regimen. Additionally, the antibiotics had to be 
prescribed on the exact same date, whereas the proton pump 
inhibitor was allowed to be prescribed within a window of 60 
days before or 5 days after the antibiotics prescription. This 
window was chosen to include individuals already using a 
proton pump inhibitor before the eradication treatment and to 
take temporary non-availability in the pharmacy into account. 
Recommended eradication regimens accounted for 95.4% of 
all eradication treatments prescribed in Sweden during the 
study period.9 The remaining 4.6% of the treatments included 
combinations of antibiotics that are not standard for H. pylori 
eradication and were therefore not included in this study.
Outcomes
The outcomes were first and primary gastric adenocarcinoma 
and non-cardia gastric adenocarcinoma diagnosed in the 
Swedish Cancer Registry during follow-up of the cohort after 
H. pylori eradication treatment, excluding tumours occurring 
within 1 year of the eradication treatment. Gastric cancer 
was defined by any of the following International Classifica-
tion of Diseases 7 (ICD7) codes: 151 (gastric cancer), 151.0 
(non-cardia gastric cancer), 151.1 (cardia cancer), 151.8 
(multifocal gastric cancer) and 151.9 (gastric cancer, not 
further specified), whereas the code for cardia cancer (151.1) 
was excluded when analysing non-cardia cancer. Adenocarci-
noma histology was determined using the code 096 from the 
C24 WHO classification of histology. Other histological types 
of gastric malignancies are not associated with H. pylori (or 
have a different level of association, eg, mucosa-associated 
lymphoid tissue lymphoma) and therefore were excluded.10 
Unfortunately, no data were available to assess the specific 
subtypes of gastric adenocarcinoma (intestinal, diffuse or 
mixed).
Confounders
Adjustments were made for age (categorised into the age 
groups 18–59, 60–69 or ≥70 years), sex (men or women) 
and calendar period (2005–2006, 2007–2009 or 2010–2012) 
by standardising these variables. Place of residence (urban or 
rural), which is correlated with socioeconomic and lifestyle 
factors,11 was analysed for influence on the outcome.
Data sources
The Swedish Prescribed Drug Registry provided information 
on H. pylori eradication treatment. This register started on 
1 July 2005 and contains information on all prescribed and 
dispensed medications for the whole Swedish population. 
Patient identifying data are missing in only <0.3% of all 
recorded prescriptions.12 Variables used were the age, sex, 
postal code (to assess place of residence),11 unique personal 
identity number of each individual and the substance, dates, 
amount and dosage of the dispensed drugs.
The Swedish Cancer Registry provided information on 
gastric and non-cardia gastric adenocarcinoma. This register 
has a completeness of 98% for recording of non-cardia adeno-
carcinoma.13 Data on the histological type and location of the 
cancer, and date and age at cancer diagnosis were used, and all 
these variables are 100% completely recorded in the register.
The Swedish Causes of Death Registry was used to assess 
dates of death. This information is virtually 100% complete 
and was used for censoring of follow-up time.14
The Swedish Patient Registry was used for information on 
gastric histology and peptic ulcer diagnoses. Codes used were 
540 (ICD7), 531 (ICD8,9) and K25 (ICD10) for gastric ulcer; 
541 (ICD7), 532 (ICD8,9) and K26 (ICD10) for duodenal 
ulcer; 543,01 (ICD7), 535,03 (ICD8), 535C and 535F (ICD9) 
and K293 and K295 (ICD10) for chronic gastritis; 535B 
(ICD9) and K294 (ICD10) for atrophic gastritis. This infor-
mation was collected from the Inpatient, Outpatient and Day 
Surgery Registries. The Swedish Inpatient Registry is nation-
wide complete since 1987 and was complemented with the 
Day Surgery Registry in 1997 and the Outpatient Registry in 
2001.15 To the best of our knowledge, no validation for gastric 
lesions is available.
statistical analysis
Standardised incidence ratios (SIRs) with 95% CIs were 
calculated as the ratio of the observed number of gastric and 
non-cardia gastric adenocarcinoma cases in the H. pylori erad-
ication cohort compared with the expected number of such 
cases in the Swedish population of the same sex, age group 
and calendar period with categorisation as presented above 
(Confounders section). Clayton’s algorithm was used to calcu-
late the follow-up time in person-years for each stratum, 
starting from the date of the first dispensed prescription of 
H. pylori eradication treatment.16 This index date was chosen 
as time zero to emulate a randomised clinical trial.17 Addi-
tionally, a ‘per-protocol’ analysis was performed which started 
from the last dispense date of eradication treatment. Indi-
viduals were followed up until the occurrence of any cancer, 
death or the end of the study period, whichever occurred first. 
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Subgroup analyses were performed for the time after eradica-
tion treatment (grouped into 1–3, 3–5 and 5–7.5 years) and 
the number of received eradication treatments (1, 2 and ≥2). 
More than one eradication treatment indicated that H. pylori 
remained present after the previous treatment attempt, thus 
prolonging the duration of infection in the individual. The risk 
of cancer in individuals with peptic ulcer (gastric or duodenal) 
or gastritis (chronic or atrophic) was also assessed.
Poisson regression was used to analyse potential confounding 
by place of residence (urban or rural) and to assess any influ-
ence of the length of follow-up presented as incidence rate 
ratios (IRRs) and 95% CIs. Using the highest estimated inci-
dence of gastric cancer in Sweden during the study period 
(17.3/100 000 individuals), we would need 121 621 person-
years to verify a risk decrease of 55%8 with 80% power and an 
alpha level of 0.05. The statistical software STATA V.13.0 was 
used for all analyses.
resulTs
Participants
The study included 95 176 individuals receiving H. pylori erad-
ication treatment during the study period (table 1). There were 
more men (53.7%) than women (46.3%) and the majority was 
younger than 60 years (60.1%). Most individuals resided in 
urban areas (74.6%). The mean length of follow-up was 3.7 
years (maximum 7.5 years). During 351 018 person-years at risk, 
75 (0.1%) individuals developed gastric adenocarcinoma and 69 
(0.1%) developed non-cardia gastric adenocarcinoma. Out of 
1235 individuals with duodenal ulcer, no one developed gastric 
adenocarcinoma, while 3 out of 732 (0.4%) with gastric ulcer 
developed gastric adenocarcinoma. Of the 1898 individuals with 
either chronic or atrophic gastritis, 2 developed gastric adeno-
carcinoma (0.1%).
H. pylori eradication treatment and risk of all gastric 
adenocarcinoma
The SIRs decreased with longer time after eradication treatment. 
The SIRs were 8.65 (95% CI 6.37 to 11.46) for 1–3 years, 2.02 
(95% CI 1.25 to 3.09) for 3–5 years and 0.31 (95% CI 0.11 
to 0.67) for 5–7.5 years after eradication treatment (table 2). 
Poisson regression with 1–3 years after eradication treatment 
as the reference group showed IRRs of 0.05 (95% CI 0.03 to 
0.09) 3–5 years and 0.00 (95% CI 0.00 to 0.01) 5–7.5 years 
after eradication treatment. Analysis from the date of last erad-
ication treatment (per protocol) showed a similar trend, with 
decreased risks from ≥5 years after eradication treatment (data 
not shown). The risk of gastric adenocarcinoma increased with 
a higher number of eradication treatments, from SIR 1.88 (95% 
CI 1.44 to 2.41) in individuals with one eradication treatment 
to SIR 7.44 (95% CI 2.72 to 16.19) in those with more than 
two eradication treatments (table 2). Poisson regression showed 
no difference in gastric adenocarcinoma risk between individuals 
residing in rural or urban areas (IRR 0.98, 95% CI 0.59 to 1.61; 
P=0.93).
Women had a higher risk of gastric adenocarcinoma 1–3 years 
after eradication treatment (SIR 11.69, 95% CI 7.49 to 17.40), 
compared with men (SIR 6.86, 95% CI 4.39 to 10.20), but the 
SIRs were similar after 3 years of follow-up (table 3). Younger 
age was associated with a higher risk of gastric adenocarcinoma, 
especially 1–3 years after eradication treatment (table 3).
Table 1 Descriptive characteristics of the cohort of individuals 
receiving at least one eradication regimen for Helicobacter pylori in 
Sweden during 2005–2012
Characteristic no of participants (%)
Total 95 176 (100.0)
Sex
  Men 44 028 (46.3)
  Women 51 148 (53.7)
Age (years)
  18–59 57 214 (60.1)
  60–69 17 808 (18.7)
  ≥70 20 154 (21.2)
Calendar period
  2005–2006 21 218 (22.3)
  2007–2009 38 573 (40.5)
  2010–2012 35 385 (37.2)
Place of residence
  Rural 23 686 (24.9)
  Urban 71 032 (74.6)
  Missing 458 (0.5)
Type of cancer
  All gastric adenocarcinoma 75 (0.08)
  Non-cardia gastric adenocarcinoma 69 (0.07)
  Cardia adenocarcinoma 6 (0.01)
Follow-up (years)
  Total 351 018
  Mean 3.7
Table 2 Risk of gastric and non-cardia gastric adenocarcinoma in individuals receiving Helicobacter pylori eradication treatment in Sweden from 
2005 to 2012 compared with the Swedish standard population, expressed as SIR with 95% CI
Gastric adenocarcinoma non-cardia gastric adenocarcinoma Cardia adenocarcinoma
no of cases sIr (95% CI) no of cases sIr (95% CI) no of cases sIr (95% CI)
Total 75 2.08 (1.63 to 2.60) 69 2.64 (2.06 to 3.35) 6 0.60 (0.22 to 1.30)
Follow-up time, years
  1–3 48 8.65 (6.37 to 11.46) 43 10.74 (7.77 to 14.46) 5 3.23 (1.04 to 7.54)
  3–5 21 2.02 (1.25 to 3.09) 20 2.67 (1.63 to 4.13) 1 0.35 (0.01 to 1.93)
  5–7.5 6 0.31 (0.11 to 0.67) 6 0.43 (0.16 to 0.93) 0 NA
No of eradications
  1 61 1.88 (1.44 to 2.41) 56 2.38 (1.80 to 3.10) 5 0.56 (0.18 to 1.30)
  2 8 2.84 (1.22 to 5.59) 7 3.45 (1.38 to 7.11) 1 1.26 (0.02 to 7.02)
  >2 6 7.44 (2.72 to 16.19) 6 10.47 (3.82 to 22.78) 0 NA
NA, not applicable; SIR, standardised incidence ratio.
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H. pylori eradication treatment and risk of non-cardia gastric 
adenocarcinoma
The SIRs of non-cardia gastric adenocarcinoma decreased with 
longer duration after eradication treatment, with SIRs of 10.74 
(95% CI 7.77 to 14.46) 1–3 years, 2.67 (95% CI 1.63 to 4.13) 
3–5 years and 0.43 (95% CI 0.16 to 0.93) 5–7.5 years after 
eradication treatment (table 2). Multiple eradication treatments 
increased the risk of non-cardia gastric adenocarcinoma, from 
SIR 2.38 (95% CI 1.80 to 3.10) in those with one eradication 
treatment to SIR 10.47 (95% CI 3.82 to 22.78) in those with 
more than two eradication treatments (table 2).
Eradication treatment for H. pylori did not influence the 
overall risk of cardia adenocarcinoma (SIR 0.60, 95% CI 0.22 to 
1.30), but there were too few cases (six cases) to provide robust 
results regarding time latencies after eradication treatment of H. 
pylori and the risk of this tumour. Due to the low number of 
gastric adenocarcinoma cases in individuals with peptic ulcer or 
gastritis, further analyses were not deemed feasible.
DIsCussIOn
This study showed that the risk of gastric adenocarcinoma and 
non-cardia gastric adenocarcinoma declined over time after erad-
ication treatment for H. pylori and was lower than that of the 
background population from 5 years after eradication treatment.
Methodological strengths of this study include the popula-
tion-based design, large sample size and the high-quality data 
in the registers used. Additionally, studies on this topic have 
rarely been performed on a Western population, thus this study 
assesses a gap of knowledge. Also, non-cardia gastric adenocar-
cinoma was analysed separately, the gastric cancer type known 
to be associated with H. pylori, which was not always the case 
in earlier studies. The study also has limitations. The registers 
do not contain information on some potential confounders, for 
example, socioeconomic status. However, there was no effect of 
place of residence, which is correlated with socioeconomic status 
and lifestyle factors like smoking, diet and physical activity. 
Another limitation was the relatively short duration of follow-up. 
However, the maximum length of follow-up was still 7.5 years 
and the study had sufficient statistical power for robust anal-
yses, including in the longest follow-up category. The fact that 
parts of the background population were infected with H. pylori 
would dilute the risk estimates, but not explain them, and this 
dilution should be limited because the population prevalence of 
H. pylori infection in Sweden is relatively low (15%).5 Further-
more, the strongly decreased risk for gastric cancer was found in 
the eradication treatment cohort, which is the group that should 
primarily be targeted (symptomatic individuals), considering the 
relatively low (3%) lifetime risk of developing gastric cancer in 
those with H. pylori. Additionally, the participants who received 
H. pylori eradication treatment were included in the background 
population, but because the study participants represented only 
a small proportion of the population (1.3%), this is unlikely to 
have had major influence on the results. If anything, it would 
again have diluted the associations and not explain them. Since 
our estimates are relative to the Swedish background popula-
tion, they cannot be directly compared with estimates of studies 
comparing eradicated individuals with non-eradicated H. pylo-
ri-positive individuals. Another limitation is the lack of infor-
mation about eradication treatments received before July 2005, 
making it unclear whether the first eradication date in the study 
was in fact the first eradication attempt. However, there is low 
antibiotic resistance in Sweden18 and only 9% of all cohort 
members received more than one eradication treatment during 
the study period, making this a minor issue. There was no confir-
mation of eradication success, meaning that H. pylori might still 
have been present after treatment. This should explain the higher 
risk among individuals receiving multiple eradication treatments 
compared with those with only one (more likely to be successful) 
eradication treatment. Detection bias could have been present 
if timing of gastric cancer diagnosis in eradicated individuals 
is different than in the background population. But since the 
majority of the background population is not infected with H. 
pylori and thus has a lower risk of gastric cancer, the decreased 
risk by time since eradication is more likely explained by the 
reasoning that once eradication treatment has prevented the 
gastric cancer development in the cohort, the background popu-
lation has a higher risk of cancer, since there will be untreated H. 
pylori-infected individuals.
The clearly decreasing risk after eradication treatment over 
time is reassuring and in line with the results of meta-anal-
yses from predominantly Asian populations.7 8Compared with 
previous cohort studies on this topic, where the largest studies 
included 3781 individuals receiving H. pylori eradication treat-
ment,19 this study is considerably larger. A randomised clinical 
trial included 1130 individuals receiving eradication treatment 
with a maximum follow-up of 14.7 years, where an OR of 0.61 
(95% CI 0.38 to 0.96) was found for gastric cancer compared 
with a placebo group (n=1128).20 However, that study did not 
analyse adenocarcinomas or non-cardia cancers separately. Of 
all previous randomised clinical trials or cohort studies, only one 
was conducted in a Western population, that is, in Finland with 
low prevalence of H. pylori and low risk of gastric cancer.21 The 
Table 3 Risk of gastric adenocarcinoma in individuals receiving Helicobacter pylori eradication treatment in Sweden from 2005 to 2012 compared 
with the Swedish standard population stratified by sex, age and calendar period, expressed as SIR with 95% CI
Time after eradication 
1–3 years 3–5 years 5–7.5 years
no of cases sIr (95% CI) no of cases sIr (95% CI) no of cases sIr (95% CI)
Total 48 8.65 (6.37 to 11.46) 21 2.02 (1.25 to 3.09) 6 0.31 (0.11 to 0.67)
Sex
  Men 24 6.86 (4.39 to 10.20) 13 2.02 (1.08 to 3.46) 4 0.34 (0.09 to 0.87)
  Women 24 11.69 (7.49 to 17.40) 8 2.03 (0.87 to 4.00) 2 0.26 (0.03 to 0.93)
Age, years
  18–59 14 25.71 (14.04 to 43.14) 4 3.57 (0.96 to 9.15) 0 NA
  60–69 8 5.95 (2.56 to 11.71) 4 1.52 (0.41 to 3.88) 1 0.18 (0.00 to 1.02)
  ≥70 26 7.10 (4.64 to 10.40) 13 1.96 (1.05 to 3.36) 5 0.43 (0.14 to 1.00)
NA, not applicable; SIR, standardised incidence ratio. 
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results of the present study are in line with the Finnish study, 
showing a strong decrease starting from the sixth year after erad-
ication therapy. However, in this study, adenocarcinoma was not 
assessed separately.
An interesting finding in this study was that women had a 
higher SIR of gastric adenocarcinoma in the first 3 years after 
eradication compared with the SIR in men. Because these are 
relative risks, this finding might be explained by the higher risk 
of gastric adenocarcinoma in the male background population 
compared with the female background population.
This study provides evidence-based information about the 
preventive effect of H. pylori eradication on the risk of gastric 
adenocarcinoma, which might be especially relevant for health-
care providers in countries with a low incidence of gastric cancer 
to help decide whether to eradicate or not. Despite the favour-
able results of eradication for low prevalence settings, we believe 
there should be caution to implement widespread eradication, 
especially in asymptomatic individuals, since the long-term nega-
tive effects of eradication are insufficiently clear. However, more 
research is needed with regards to what would be the best point 
in time for eradication treatment, and if there is a so-called ‘point 
of no return’ in the developmental pathway to gastric cancer. 
Potential harmful effects of H. pylori eradication treatment need 
also to be clarified, and the inverse association between H. pylori 
infection and the risk of oesophageal adenocarcinoma should 
not be forgotten.
In conclusion, this population-based Swedish cohort study 
showed a sharp decrease in risk of gastric adenocarcinoma and 
non-cardia gastric adenocarcinoma after eradication treatment 
for H. pylori. The risk was below the level of the background 
population 5 years after the eradication treatment. Thus, eradi-
cation treatment for H. pylori seems to prevent the development 
of gastric and non-cardia gastric adenocarcinoma also in Western 
populations.
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